STOCK TITAN

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Wave Life Sciences Ltd. will host a live webcast and conference call to discuss its fourth quarter and full year 2023 financial results and business updates on March 6, 2024. The event aims to provide insights into the company's performance and future prospects in the RNA medicines sector.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 6, 2024, to review the company’s fourth quarter and full year 2023 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline, and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.  

Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com


FAQ

When will Wave Life Sciences host a live webcast and conference call to discuss its financial results?

Wave Life Sciences will host a live webcast and conference call on March 6, 2024, at 8:30 a.m. ET.

Where can analysts access the webcast and conference call?

Analysts can access the webcast and conference call by visiting the 'Investor Events' section on the Wave Life Sciences website.

How can participants join the Q&A portion of the live call?

Participants can join the Q&A portion of the live call by registering at the provided audio conferencing link.

Will an archived version of the webcast be available after the live event?

Yes, an archived version of the webcast will be available on the Wave Life Sciences website after the live event.

Wave Life Sciences Ltd. Ordinary Shares

NASDAQ:WVE

WVE Rankings

WVE Latest News

WVE Stock Data

2.16B
129.41M
15.04%
78.49%
4.48%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SINGAPORE